These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 26140185)

  • 1. TP53 Binding to BRCA1 and RAD51 in MCF7 and MDA-MB-468 Breast Cancer Cell Lines In vivo and In vitro.
    Rasti M; Azimi T
    Avicenna J Med Biotechnol; 2015; 7(2):76-9. PubMed ID: 26140185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comparative study on functional characters of MCF7 and HCC1937 cell lines in response to DNA damage].
    Dong C; Zhang F; Zhao X; Guo G; Luo Y; Feng Z
    Zhonghua Yu Fang Yi Xue Za Zhi; 2014 Sep; 48(9):809-14. PubMed ID: 25492294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gain of function mutant p53 proteins cooperate with E2F4 to transcriptionally downregulate RAD17 and BRCA1 gene expression.
    Valenti F; Ganci F; Fontemaggi G; Sacconi A; Strano S; Blandino G; Di Agostino S
    Oncotarget; 2015 Mar; 6(8):5547-66. PubMed ID: 25650659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. UBE2Q1 in a Human Breast Carcinoma Cell Line: Overexpression and Interaction with p53.
    Shafiee SM; Rasti M; Seghatoleslam A; Azimi T; Owji AA
    Asian Pac J Cancer Prev; 2015; 16(9):3723-7. PubMed ID: 25987028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
    Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
    Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Characterization of BRCA1 c.5339T>C Missense Mutation in DNA Damage Response of Triple-Negative Breast Cancer.
    Lee JD; Ryu WJ; Han HJ; Kim TY; Kim MH; Sohn J
    Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA damage response markers are differentially expressed in BRCA-mutated breast cancers.
    Aleskandarany M; Caracappa D; Nolan CC; Macmillan RD; Ellis IO; Rakha EA; Green AR
    Breast Cancer Res Treat; 2015 Feb; 150(1):81-90. PubMed ID: 25690937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of interaction of mutant TP53 and wild type BRCA1 by alkaloids: a computational approach towards targeting protein-protein interaction as a futuristic therapeutic intervention strategy for breast cancer impediment.
    Tiwari S; Awasthi M; Singh S; Pandey VP; Dwivedi UN
    J Biomol Struct Dyn; 2018 Oct; 36(13):3376-3387. PubMed ID: 28978265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of human breast cancer cell lines for the studies on p53 in chemical carcinogenesis.
    Huovinen M; Loikkanen J; Myllynen P; Vähäkangas KH
    Toxicol In Vitro; 2011 Aug; 25(5):1007-17. PubMed ID: 21457773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA1 interactors, RAD50 and BRIP1, as prognostic markers for triple-negative breast cancer severity.
    Katheeja MN; Das SP; Das R; Laha S
    Front Genet; 2023; 14():1035052. PubMed ID: 36873936
    [No Abstract]   [Full Text] [Related]  

  • 11. Role of Lactate in the Regulation of Transcriptional Activity of Breast Cancer-Related Genes and Epithelial-to-Mesenchymal Transition Proteins: A Compassion of MCF7 and MDA-MB-231 Cancer Cell Lines.
    San-Millan I; Martinez JL; Pickard SL; Yu H; Hirsch FR; Rivard CJ; Brooks GA
    bioRxiv; 2023 Sep; ():. PubMed ID: 36993762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
    Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
    Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polyethylene glycol conjugated insulin-like growth factor binding protein-1 (IGFBP-1) inhibits growth of breast cancer in athymic mice.
    Van den Berg CL; Cox GN; Stroh CA; Hilsenbeck SG; Weng CN; McDermott MJ; Pratt D; Osborne CK; Coronado-Heinsohn EB; Yee D
    Eur J Cancer; 1997 Jun; 33(7):1108-13. PubMed ID: 9376191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential regulation of DNA repair protein Rad51 in human tumour cell lines exposed to doxorubicin.
    Koehn H; Magan N; Isaacs RJ; Stowell KM
    Anticancer Drugs; 2007 Apr; 18(4):419-25. PubMed ID: 17351394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein.
    Alshareeda AT; Negm OH; Aleskandarany MA; Green AR; Nolan C; TigHhe PJ; Madhusudan S; Ellis IO; Rakha EA
    Breast Cancer Res Treat; 2016 Aug; 159(1):41-53. PubMed ID: 27464795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PARG deficiency is neither synthetic lethal with BRCA1 nor PTEN deficiency.
    Noll A; Illuzzi G; Amé JC; Dantzer F; Schreiber V
    Cancer Cell Int; 2016; 16():53. PubMed ID: 27375368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction of p53 with the human Rad51 protein.
    Buchhop S; Gibson MK; Wang XW; Wagner P; Stürzbecher HW; Harris CC
    Nucleic Acids Res; 1997 Oct; 25(19):3868-74. PubMed ID: 9380510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous ATM/BRCA1/RAD51 expression variations associated with prognostic factors in Iranian sporadic breast cancer patients.
    Hallajian Z; Mahjoubi F; Nafissi N
    Breast Cancer; 2017 Jul; 24(4):624-634. PubMed ID: 28058614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution.
    Greenblatt MS; Chappuis PO; Bond JP; Hamel N; Foulkes WD
    Cancer Res; 2001 May; 61(10):4092-7. PubMed ID: 11358831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular trail for the anticancer behavior of a novel copper carbohydrazone complex in BRCA1 mutated breast cancer.
    Nair RS; Potti ME; Thankappan R; Chandrika SK; Kurup MR; Srinivas P
    Mol Carcinog; 2017 May; 56(5):1501-1514. PubMed ID: 28052399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.